SEC Filing Summary: AVI BioPharma, Inc. (10-Q)
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended March 31, 2002, for AVI BioPharma, Inc. (Note: The input metadata referenced "Sarepta Therapeutics," but the filing text explicitly identifies the registrant as AVI BioPharma, Inc.). The company is classified as a "Development Stage Company" focused on research and development (R&D) with no material product revenues. It has been unprofitable since its inception in July 1980.
Key Financial Metrics
| Metric | Q1 2002 | Q1 2001 | YTD Inception to Mar 31, 2002 |
|---|---|---|---|
| Revenues | $237,695 | $15,980 | $3,082,352 |
| Net Loss | $(7,816,093) | $(3,178,710) | $(95,035,100) |
| Net Loss Per Share | $(0.33) | $(0.15) | N/A |
| Operating Expenses | $8,133,639 | $3,556,746 | $89,252,318 |
| Cash & Equivalents (End of Period) | $29,885,643 | $22,001,736 | $29,885,643 |
| Total Assets | $45,137,124 | N/A | N/A |
| Accumulated Deficit | $(95,035,100) | N/A | $(95,035,100) |
Liquidity: Total cash, cash equivalents, and short-term securities totaled $37,825,328 as of March 31, 2002. The company has no credit facility.
Material Changes vs. Prior Period
- Revenue Growth: Revenues increased significantly to $237,695 from $15,980 in Q1 2001, driven by higher grants and research contract revenues.
- Expense Surge: Operating expenses more than doubled to $8.13 million from $3.56 million. R&D expenses rose to $7.05 million (from $2.59 million), primarily due to $4 million in GMP manufacturing costs for NEUGENES for Phase III trials and the Resten-NG product.
- Financing Activity: The company closed a private equity financing on March 25, 2002, raising net proceeds of $21,379,500. This involved selling 3,070,671 shares at $7.50 per share and issuing warrants for 614,139 shares.
- Investment Valuation: The fair market value of the company's investment in SuperGen, Inc. dropped from $6.41 million (Dec 31, 2001) to $2.52 million (Mar 31, 2002), contributing to a decrease in accumulated other comprehensive income.
Outlook, Risks, and Management Commentary
- Future Losses: Management expects to continue incurring losses for the foreseeable future as R&D activities expand. No material product revenues are expected for at least the next 12 months.
- Capital Requirements: Estimated expenditures for 2002 are approximately $20 million, with 2003 expected to be equal to or greater than 2002. The company expects existing cash resources to cover requirements for the next 12 months but may need to raise additional capital thereafter.
- Risks: Key risks include the volatility of clinical trial results, regulatory approval timelines, the ability to commercialize products, and the volatility of the SuperGen, Inc. investment.
- Warrant Extensions: On March 5, 2002, the expiration dates for AVIIW and AVIIZ warrants were extended to September 3, 2002, and August 15, 2003, respectively.
Investor Verification Checklist
- Verify the status and timeline of Phase III clinical trials for NEUGENES and the commercial launch plans for Resten-NG.
- Confirm the current valuation and liquidity of the SuperGen, Inc. investment, given its historical volatility.
- Monitor the company's cash burn rate against the $20 million 2002 expenditure estimate to assess the need for future dilutive financing.
- Review the terms of the private equity financing closed in March 2002, specifically the warrant exercise price ($10.50) and expiration (March 2006).
- Check for any updates on the registration statement (Form S-3) filed for the resale of the private placement securities.